Tempus AI Strikes $200M Pharma Deal—Will Its Foundation Models Help Revolutionize Cancer Treatment?

Tempus’ first-quarter financial results for 2025 reveal a complex yet promising outlook. The company saw a significant increase in quarterly revenue, which rose by 75.4% year-over-year to $255.7 million. Genomics emerged as a key driver, growing by 89% year-over-year to $193.8 million. Tempus’ oncology testing and hereditary testing segments reported growth rates of 31% and 23%, respectively. Additionally, revenue from data and services increased by 43%, largely propelled by the data licensing business.